CLV

Clinuvel Pharmaceuticals ADR

Stock
Stock
ISIN: US1887691038
Ticker: CLVLY
US1887691038
CLVLY

Price

Dividend metrics

Annual payout (TTM) 
$0.034
Yield (TTM) 
0.475%
Payout ratio 
7.275%
Payout frequency 
Annually
Dividend growth (3Y) 
21.16%
Next payment 
$0.034

Dividend history & forecast

$0.0262

CHART BY


Status

Ex-date

Pay Date

Yield

% Change

Amount

20250.35%0%$0.034
Forecasted09.09.202530.09.20250.35%0%$0.034
20240.35%+4.81%$0.034
Paid09.09.202430.09.20240.35%+4.81%$0.034
20230.3%+21.62%$0.0324
Paid07.09.202302.10.20230.3%+21.62%$0.0324
20220.18%+46.28%$0.0267
Paid09.09.202203.10.20220.18%+46.28%$0.0267
20210.07%-0.03%$0.0182
Paid03.09.202127.09.20210.07%-0.03%$0.0182
20200.14%-8.87%$0.0182
Paid07.09.202028.09.20200.14%-8.87%$0.0182
2019--$0.02
Paid06.09.201930.09.2019--$0.02

Frequently asked questions

When does Clinuvel Pharmaceuticals ADR pay dividends?

Clinuvel Pharmaceuticals ADR's dividends are paid out in October.

How often does Clinuvel Pharmaceuticals ADR pay dividends?

Annually

What is the dividend yield of Clinuvel Pharmaceuticals ADR?

The dividend yield is currently 0.47% and distributions have increased by 21.16% in the last 3 years.

When was Clinuvel Pharmaceuticals ADR's last dividend payout date?

The last payment was made on 30.09.2024.

When do you have to have Clinuvel Pharmaceuticals ADR in your portfolio to receive the last dividend?

If you had Clinuvel Pharmaceuticals ADR in your securities account on 09.09.2024, you received the distribution.

How much was Clinuvel Pharmaceuticals ADR's dividend in 2023?

Clinuvel Pharmaceuticals ADR paid out a dividend of $0.0324 in 2023.

How much was Clinuvel Pharmaceuticals ADR's dividend in 2022?

Clinuvel Pharmaceuticals ADR paid out a dividend of $0.0267 in 2022.

What is Clinuvel Pharmaceuticals ADR's next dividend?

Clinuvel Pharmaceuticals ADR has not yet announced a next dividend payment yet.

Dividend growth 

1 Year

Strong growth21.62%

3 Year

Strong growth21.16%

5 Year

-

10 Year

-

Other top dividend stocks

Join the conversation